What changed
$NVS — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $3.5B | EPS $1.99 vs $2.07 🔴
💡 Consensus expects further earnings erosion and margin pressure, but underlying ex-FX growth remains robust, and FY guidance was maintained. The market is pricing in a lasting negative shift that base rates for similar pharma misses suggest is unlikely.
📉 Reward/risk: 2.0:1
🏢 Business Quality: 8/10 - Diversified pharma giant with durable franchises, high-margin biologics, and a deep late-stage pipeline, balanced by patent-cliff risks in certain segments.
📊 Valuation: fair-to-cheap: post-miss P/E of ~18.5x on normalized $8.00 2026 EPS compares to 5-year average of 20x and peer median of 16x; FCF yield ~6% supports...
🔮 Catalyst: Q3 2026 earnings release
💰 Entry: $153.38, stop $145.0, target $170.0
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/NVS0623